MX2022014575A - Tratamiento para la esteatohepatitis no alcoholica (nash). - Google Patents
Tratamiento para la esteatohepatitis no alcoholica (nash).Info
- Publication number
- MX2022014575A MX2022014575A MX2022014575A MX2022014575A MX2022014575A MX 2022014575 A MX2022014575 A MX 2022014575A MX 2022014575 A MX2022014575 A MX 2022014575A MX 2022014575 A MX2022014575 A MX 2022014575A MX 2022014575 A MX2022014575 A MX 2022014575A
- Authority
- MX
- Mexico
- Prior art keywords
- nash
- alcoholic steatohepatitis
- treatment
- methods
- 25hc3s
- Prior art date
Links
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title abstract 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 title abstract 3
- PIUZYOCNZPYXOA-ZHHJOTBYSA-N [(3s,8s,9s,10r,13r,14s,17r)-17-[(2r)-6-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCCC(C)(C)O)C)[C@@]1(C)CC2 PIUZYOCNZPYXOA-ZHHJOTBYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
Se proporcionan métodos para el tratamiento de la esteatohepatitis no alcohólica (NASH). Por ejemplo, los métodos comprenden administrar 5-colesten-3,25-diol, 3-sulfato (25HC3S) o una sal del mismo.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063029361P | 2020-05-22 | 2020-05-22 | |
| US202063030207P | 2020-05-26 | 2020-05-26 | |
| US202063113116P | 2020-11-12 | 2020-11-12 | |
| US202163146555P | 2021-02-05 | 2021-02-05 | |
| PCT/US2021/033743 WO2021237143A1 (en) | 2020-05-22 | 2021-05-21 | Treatment of non-alcoholic steatohepatitis (nash) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014575A true MX2022014575A (es) | 2022-12-15 |
Family
ID=78707644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014575A MX2022014575A (es) | 2020-05-22 | 2021-05-21 | Tratamiento para la esteatohepatitis no alcoholica (nash). |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230181601A1 (es) |
| EP (1) | EP4153164A4 (es) |
| JP (1) | JP2023527153A (es) |
| KR (1) | KR20230015939A (es) |
| CN (1) | CN115916181A (es) |
| AU (1) | AU2021273936A1 (es) |
| BR (1) | BR112022022737A2 (es) |
| CA (1) | CA3195103A1 (es) |
| MX (1) | MX2022014575A (es) |
| TW (1) | TW202210081A (es) |
| WO (1) | WO2021237143A1 (es) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
| US8399441B2 (en) * | 2004-10-25 | 2013-03-19 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis |
| WO2006047022A1 (en) * | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| US9034859B2 (en) * | 2011-04-06 | 2015-05-19 | Virginia Commonwealth University | Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation |
| EP2755480B1 (en) * | 2011-09-16 | 2021-03-31 | Galectin Therapeutics Inc. | Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease |
| CN105592846A (zh) * | 2013-03-15 | 2016-05-18 | 持田制药株式会社 | 用于治疗非酒精性脂肪性肝炎的组合物和方法 |
| JP2019524772A (ja) * | 2016-08-02 | 2019-09-05 | ヴァージニア コモンウェルス ユニバーシティ | ５−コレステン−３，２５−ジオール，３−サルフェート（２５ｈｃ３ｓ）又は薬学的に許容される塩及び少なくとも１種の環状オリゴ糖を含む組成物 |
-
2021
- 2021-05-21 AU AU2021273936A patent/AU2021273936A1/en active Pending
- 2021-05-21 TW TW110118457A patent/TW202210081A/zh unknown
- 2021-05-21 KR KR1020227043976A patent/KR20230015939A/ko active Search and Examination
- 2021-05-21 WO PCT/US2021/033743 patent/WO2021237143A1/en unknown
- 2021-05-21 BR BR112022022737A patent/BR112022022737A2/pt not_active Application Discontinuation
- 2021-05-21 JP JP2022570474A patent/JP2023527153A/ja active Pending
- 2021-05-21 CA CA3195103A patent/CA3195103A1/en active Pending
- 2021-05-21 CN CN202180049351.XA patent/CN115916181A/zh active Pending
- 2021-05-21 EP EP21808175.0A patent/EP4153164A4/en active Pending
- 2021-05-21 MX MX2022014575A patent/MX2022014575A/es unknown
- 2021-05-21 US US17/924,101 patent/US20230181601A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022022737A2 (pt) | 2023-01-31 |
| WO2021237143A1 (en) | 2021-11-25 |
| EP4153164A1 (en) | 2023-03-29 |
| CN115916181A (zh) | 2023-04-04 |
| US20230181601A1 (en) | 2023-06-15 |
| EP4153164A4 (en) | 2024-06-26 |
| AU2021273936A1 (en) | 2022-12-08 |
| TW202210081A (zh) | 2022-03-16 |
| JP2023527153A (ja) | 2023-06-27 |
| KR20230015939A (ko) | 2023-01-31 |
| CA3195103A1 (en) | 2021-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018022668A3 (en) | NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER | |
| BR112021011684A2 (pt) | Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda | |
| MX2021005075A (es) | Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion. | |
| MX2009009816A (es) | Anticuerpos monoclonales para el tratamiento del cancer. | |
| MX2011009757A (es) | Metodo para tratar esteatohepatitis no alcoholica con elevadas dosis de acido ursodeoxicolico. | |
| MX2009009636A (es) | Metodos para tratar enfermedades oftalmicas. | |
| JOP20220013A1 (ar) | علاج توليفي ينطوي على استخدام الأجسام المضادة ضد claudin 18.2 ومثبطات نقاط الفحص المناعي لعلاج السرطان | |
| BR112019023909A2 (pt) | método para tratamento de um paciente com câncer de ovário, câncer peritoneal ou câncer de trompa de falópio. | |
| BR112021014699A2 (pt) | Métodos de tratamento de mieloma múltiplo | |
| EA202092540A1 (ru) | Комбинации для лечения рака | |
| MX2023008193A (es) | Procedimientos para tratar el cáncer. | |
| NZ625758A (en) | Method for treating breast cancer | |
| MX2022014180A (es) | Metodos, terapias y usos para tratar cancer. | |
| MX2022014574A (es) | Tratamiento para la esteatohepatitis no alcoholica (nash). | |
| MX2022014575A (es) | Tratamiento para la esteatohepatitis no alcoholica (nash). | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
| MX2020003243A (es) | Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada. | |
| MX2021011529A (es) | Chiauranib para el tratamiento de cáncer de pulmón microcítico. | |
| MX2022003778A (es) | Tratamiento de la hepatitis alcoholica. | |
| WO2021237149A3 (en) | Treatment of non-alcoholic steatohepatitis (nash) | |
| MX2021000935A (es) | Composiciones y metodos terapeuticos para el tratamiento de cancer pancreatico con acido 6,8-bis(bencilsulfanil)octanoico. | |
| WO2019053613A3 (en) | Combination treatment for cancer | |
| MX2019015849A (es) | Nuevos compuestos de espirolactona. | |
| CR20230450A (es) | Terapia de combinación que implica anticuerpos contra claudina 18.2 para el tratamiento del cáncer | |
| MX2023003034A (es) | Metodos, terapias y usos para tratar el cancer. |